Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
25%
Ph not_applicable
1
25%
Ph phase_3
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Other(1)

Detailed Status

Completed2
unknown1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (33.3%)
Phase 31 (33.3%)
N/A1 (33.3%)

Trials by Status

completed250%
unknown125%
not_yet_recruiting125%

Recent Activity

0 active trials
Showing 4 of 4
not_yet_recruitingnot_applicable

Efficacy and Safety of Thalidomide for Pediatric PFAPA Syndrome

NCT07476625
completed

Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients

NCT07321613
unknownphase_2

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

NCT06231680
completedphase_3

the Efficiency of Thalidomide for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular Malformation

NCT02707484

Clinical Trials (4)

Showing 4 of 4 trials
NCT07476625Not Applicable

Efficacy and Safety of Thalidomide for Pediatric PFAPA Syndrome

Not Yet Recruiting
NCT07321613

Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients

Completed
NCT06231680Phase 2

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Unknown
NCT02707484Phase 3

the Efficiency of Thalidomide for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular Malformation

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4